Impact of Smoking on Salivary Interleukin (IL)-39, IL-41, IL-1β, TNF-α Levels in Periodontal Disease

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

September 15, 2024

Conditions
Periodontitis, AdultSmokingPeriodontal Diseases
Interventions
DIAGNOSTIC_TEST

Clinical Measurements and Saliva Sample Collection

"Saliva samples will be collected from all participants, and comprehensive clinical parameters will be meticulously documented. The Plaque Index (PI) and Gingival Index (GI) will be measured at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be recorded in detail for each tooth at six sites. The percentage of bleeding areas will be assessed within 20 seconds post-probing using a binary scoring system to indicate presence or absence. All clinical parameters will be recorded by a calibrated periodontologist utilizing manual probing techniques.~Following collection, saliva samples will be stored at -80°C until subsequent analysis. Concentrations of IL-39, IL-41, IL-1β, and TNF-α in the saliva samples will be quantified using specific enzyme-linked immunosorbent assay (ELISA) kits."

All Listed Sponsors
lead

Necmettin Erbakan University

OTHER

NCT06528522 - Impact of Smoking on Salivary Interleukin (IL)-39, IL-41, IL-1β, TNF-α Levels in Periodontal Disease | Biotech Hunter | Biotech Hunter